PR
ARQT icon

PSP Research’s Arcutis Biotherapeutics ARQT Stock Holding History

PSP Research’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$517K Hold
19,700
– – 0.27% 16
2026
Q1 		$464K Buy
19,700
+984
+5% +$25.1K 0.33% 29
2025
Q4 		$544K Buy
+18,716
New +$479K 0.48% 17

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PSP Research's ARQT Position: Q2 2026 in Review

PSP Research held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 19,700 shares worth $517K. The position accounts for 0.27% of the portfolio, ranked #16.

PSP Research first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $544K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • PSP Research held 19,700 shares of Arcutis Biotherapeutics worth $517K as of Q2 2026.
  • PSP Research left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up 0.27% of PSP Research's portfolio in Q2 2026, its #16 holding.
  • PSP Research first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Arcutis Biotherapeutics position peaked at $544K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.